Preapproval inspections to focus on data integrity and fraud
This article was originally published in The Gold Sheet
CDER official Rick Friedman asserted that FDA's action was prompted by recent criminal investigations, including the Department of Justice's prosecution in March 2007 of a former vice-president in charge of quality control and three supervisory chemists who pleaded guilty to conspiracy involving the rampant falsification of records. "We have found other deficiencies including acceptance of failed runs," reported Friedman at a June 23 conference in New Brunswick N.J. sponsored by Pharma Conference and the University of Rhode Island College of Pharmacy. "This has shown that many of these investigations are undermining the safety and efficacy of these products." Other examples of fraud include biased manipulation of study data, alternating weights of samples and changing weights of standardized samples. To combat this problem, FDA is "reinvigorating" specialized training of investigational staff to address data integrity, manipulation and fraud issues. Friedman recommended that manufacturers "train employees in proper data handling and reporting. Employees need to know how to identify suspect data in clinical trials and how to identity suspect GMP data. Everyone in the organization needs to be responsible for data integrity
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.